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Abstract
Background: The L1 cell adhesion molecule (L1CAM) was originally identified as a neural adhesion molecule
involved in axon guidance. In many human epithelial carcinomas L1CAM is overexpressed and thereby augments
cell motility, invasion and metastasis formation. L1CAM positive carcinomas are associated with bad prognosis.
Recent data point out that L1CAM is regulated in a fashion similar to epithelial-mesenchymal transition (EMT).
Previous studies have implied the transcription factors Slug and/or b-catenin in L1CAM transcriptional regulation.
However, the regulation of human L1CAM expression at the transcriptional level is not well understood.
Results: To better understand the molecular basis of L1CAM transcriptional regulation, we carried out a detailed
characterization of the human L1CAM promoter. We identified two transcription start sites, the first in front of a
non-translated exon 0 (promoter 1) and the other next to the first protein-coding exon 1 (promoter 2). Both sites
could be verified in endometrial carcinoma (EC) cell lines and appear to be used in a cell-type specific manner. The
two identified promoter regions showed activity in luciferase reporter assays. Chromatin-IP analyses confirmed the
in silico predicted E-boxes, binding sites for transcription factors Snail and Slug, as well as Lef-1 sites, which are
related to b-catenin-mediated transcriptional regulation, in both promoters. Overexpression of b-catenin exclusively
augmented activity of promoter 1 whereas Slug enhanced promoter 1 and 2 activity suggesting that both
promoters can be active. Overexpression of b-catenin or Slug could upregulate L1CAM expression in a cell-type
specific manner.
Conclusions: Our results, for the first time, provide evidence that the L1CAM gene has two functionally active
promoter sites that are used in a cell-type specific manner. Slug and b-catenin are involved L1CAM transcriptional
regulation. Nevertheless, Slug rather than b-catenin levels are correlated with L1CAM expression in EC cell lines.
Our findings suggest that the L1CAM transcriptional regulation is more complex than anticipated and this study
provides the basis for a better understanding of L1CAM regulation in non-neuronal/tumor cells.
Background
The integrity and plasticityo fn o r m a le p i t h e l i a lc e l l
layers is tightly controlled by cell-cell contacts mediated
by cell surface receptors that are collectively referred to
as cell adhesion molecules. The breakdown of epithelial
cell homeostasis during aggressive cancer progression is
correlated with loss of epithelial characteristics and fre-
quently leads to a disregulated expression of cell adhe-
sion receptors. A well-studied example is the loss of E-
Cadherin expression especially in adherens junctions
during epithelial-mesenchymal transition that is thought
to precede the onset of tumour metastasis [1,2].
The neural cell adhesion molecule L1CAM plays a
fundamental role in the development of the nervous sys-
tem [3,4]. Whereas in normal epithelium the L1CAM
expression is very low and hardly detectable, this
changes after neoplastic transformation. Indeed, overex-
pression of L1CAM has been reported in carcinomas
such as ovarian and endometrial, colon, pancreas, kid-
ney, cholangiocarcinoma, gastric cancer but also mela-
noma [5-9]. Wherever investigated, the expression of
L1CAM was associated with bad prognosis suggesting
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gression. The mechanisms by which L1CAM mediates
these effects are not clearly established. But work from
experimental systems showed that L1CAM augments
tumour growth in NOD/SCID mice, enhances cell moti-
lity on extracellular matrix proteins and increases matri-
gel invasion [10-13]. Other studies reported L1CAM-
dependent gene expression signatures, metastasis forma-
tion [13-15] and an augmented resistance to apoptotic
stimuli [16,17]. This raises the important question how
L1CAM expression is regulated in human tumours.
The L1CAM gene is located at chromosome Xq28
spanning about 25 kb with 28 coding exons [18,19].
Most insights into the L1CAM gene organisation and
regulatory elements were obtained in the field of neuro-
biology. Initial work on the organization of the 5′-end of
the gene has placed a transcription initiation site in
front of exon 1 that encodes the ATG in adult mouse
brain and N2A neuroblastoma cells [20]. A fragment
encompassing this region displayed promoter activity
but a second promoter was suggested > 5kb upstream
of the latter site [20]. Subsequent work has confirmed
the presence of a promoter element more than 10 kb
upstream, in front of the non-translated exon 0 [21].
Importantly, the existence of a second transcription
start site (TSS) in front of exon 1 was put into question.
The organisation of the L1CAM gene was found to be
similar between human and mouse [21].
In immunohistochemical sections, L1CAM expression
is often seen at the invasive front where the tumour
invades into the surrounding stroma [12,22-24]. Cells at
the invasive front are often enriched for nuclear b-cate-
nin localisation in contrast to the more central tumour
areas, e.g. in colon tumours [25]. Indeed, L1CAM was
identified as a target gene of the Wnt/b-catenin signal-
ling pathway [12] and nuclear b-catenin was shown to
co-localise with L1CAM [23]. This work has suggested
that the b-catenin/TCF-LEF transcriptional complex
may be an important direct regulator of L1CAM expres-
sion. Recent studies have shown that an alternative
pathway of L1CAM transcriptional regulation may exist.
The treatment of endometrial carcinoma cells with the
EMT-inducer TGF-b1a u g m e n t e dL 1 C A Me x p r e s s i o n
and downregulation of E-Cadherin and this process was
blocked by knockdown of Slug [24,26]. In pancreatic
carcinoma cells TGF-b1 treatment also upregulated
L1CAM and that was prevented by knockdown of Slug
[26]. Thus, b-catenin/TCF-LEF and Slug are implicated
in the transcriptional regulation of L1CAM but it is
unknown how this is coordinated.
The promoter organisation of the human L1CAM
gene is not fully understood.W et h e r e f o r ei n t e n d e dt o
clarify the transcriptional regulation of L1CAM as well
as whether there are alternative promoter regions. In
particular, we analysed binding sites for the transcrip-
tion factors b-catenin/TCF-LEF and Slug in the human
promoter. We provide evidence for two TSS and two
active elements in the human L1CAM promoter. Pro-
moter 1 and promoter 2 are differentially used in
human endometrial cell lines. Whereas promoter 1 is
most responsive to b-catenin overexpression and to a
lesser extent by Slug, promoter 2 is activated only by
Slug. Our results provide the basis for a better under-
standing of L1CAM regulation in tumours.
Methods
Cell lines, cell culture and transfections
ECC-1 and Hec-1A cells were maintained in DMEM/
F12 medium (PAA Laboratories, Pasching, Austria) sup-
plemented with 10% fetal calf serum, Hec-1B and
SPAC-1L cells in RPMI-1640 (PAA Laboratories, Pasch-
ing, Austria) with 10% fetal calf serum at 37°C, 5% CO2
and 100% humidity. All other endometrial carcinoma
cell lines were described before [24,27]. Transient trans-
fection of ECC-1 and Hec-1A cells was done using jet-
PEI (Polyplus, Illkirch, F). 1x10
5 cells were seeded 24 h
before transfection in 6-well plates. For luciferase assays
cells were transfected with 2 μgo ft h ec o r r e s p o n d i n g
firefly-luciferase-construct (in pGl3-basic vector), 20 ng
of renilla luciferase and if indicated 1 μgS n a i l - H A ,
Slug-HA or b-catenin construct, respectively. (Snail-HA
and Slug-HA constructs were kindley provided by Dr.
Herreros, Barcelona, Spain). The b-catenin (S33Y) plas-
mid was a gift of Dr. Avri BenZeev, Weizmann Institute,
Rehovot, Israel. The transfections were done as indi-
cated in the manufacturer’s protocol. For ChIP assays,
cells were seeded in 175 cm
2 dishes, transfected either
with pcDNA3 control, b-catenin (S33Y) or Slug-HA,
respectively. Cells were harvested 72 h after transfection.
For induction of EMT cells were cultivated in medium
in the presence of TGF-b1(10 ng/ml) for 5 days prior to
luciferase transfection.
Chemicals and antibodies
Antibodies to the ectodomain of L1CAM (monoclonal
antibody (mAb) L1-11A, a subclone of UJ127.11), were
described before [10,15]. ChIP-grade antibodies against
HA, b-catenin and Histone-H3 were obtained from Cell
Signaling Technology (Danvers, MA, USA). Antibodies
for detection in Western blot against b-catenin were
from Sigma-Aldrich (Schnelldorf, Germany) and against
GAP-DH from SantaCruz Biotechnology (Heidelberg,
Germany).
Construction of Reporter Plasmids
Promoter-1 constructs: Primers for PCR from a bacterial
artificial chromosome (Xq28: RZPDB737A112189D)
clone were as follows: P1 fw 5′-tagtatACGCGTcaaagg
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cgtcttctgca-3′;P 3f w5 ′-tagtatACGCGTtgggctttggttttct
catc-3′; Promoter-1 rev 5′-tagtatCTCGAGctgcggcag-
cagcggct-3′. Forward primers contain a MluI site (capital
letters) and reverse primer contains an XhoI site (capital
letters). PCR fragments were digested and directly
cloned into pGl3-basic vector by MluI and XhoI site.
Promoter-2 constructs: Primers for PCR from a bacterial
artificial chromosome (Xq28: RZPDB737A112189D)
clone were as follows: L1-A fw 5′-GGTACCttgggaccg-
gacttactcag-3′;L 1 - Bf w5 ′-GGTACCgatatgagcctgtggg
gaga-3′;L 1 - Cf w5 ′-GGTACCaactgctgacctcatgatcc-3′;
L1-D fw 5′-GGTACCgcagatccacaaccacacac-3′;L 1 - D *f w
5′-GGTACCgcacatgcagacacatacgg-3′;L 1 - Ef w5 ′-GGTA
CCcgggcttacccagatgttag-3′;L 1 - Ff w5 ′-GGTACCttc
tcccctctcccagtg-3′; Promoter-2 rev 5′-AAGCTTagga
gaggccacacgtacc-3′. Forward primers contain a KpnI site
(capital letters), reverse primer contains a HindIII site
(capital letters). PCR fragments were subcloned in
TOPOblunt vector (Invitrogen, Karlsruhe, Germany),
digested by HindIII and KpnI and subsequently cloned
into pGl3-basic vector. All constructs were sequenced
for control purposes.
Luciferase assay
Cells were lysed 48 h after transfection, and firefly and
renilla luciferase (pRL-TK) levels were determined by
enzyme assay kit from Promega (Dual luciferase assay
kit). Luciferase activity was normalized to renilla activity.
Co-transfection with renilla luciferase served as a trans-
fection efficiency control. Activities were calculated as a
quotient of firefly by renilla counts and were set in rela-
tion to the positive control pGl3-SV40-Luc (100%).
Quantitative RT- PCR
10 ng of total cDNA were analysed in triplicates.
L1CAM, Snail, Slug, and b-catenin specific primers for
qPCR were designed with the DNA Star Program and
were produced by MWG Eurofines (Ebersberg, Ger-
many). The PCR reaction was performed with the
SYBRgreen mastermix (Applied Biosystems, Darmstadt,
Germany) in an ABI 7300 analyser. Primers used for
determining mRNA expression levels were as follows:
L1-CAM fw 5′-ACGAGGGATGGTGTCCACTTCAA
A-3′;L 1 - C A Mr e v5 ′-TTATTGCTGGCAAAGCAG
CGGTAG-3′;S N A I Lf w5 ′-CTGCTCCACAAGCACCA
AGAGTC-3′;S N A I Lr e v5 ′-CCAGCTGCCCTCCCTC
CAC-3′;S L U Gf w5 ′-ATATTCGGACCCACACAT-
TACCT-3′;S L U Gr e v5 ′-GCAAATGCTCTGTTGCAG
TGA-3′; b-catenin fw 5′-TGCAGTTCGCCTTCAC
TATGGACT-3′; b-catenin rev 5′-GATTTGCGGGA
CAAAGGGCAAGAT-3′; and for normalisation b-actin
fw 5′-ACAAGATGAGATTGGCATGGC-3′; b-actin rev
5′-GCCACATTGTGAACTTTGGGG-3′.T oa n a l y s e
changes in gene expression in a given sample relative to
a reference sample, the comparative Ct method was
used as the relative quantification method. For correla-
tion analysis the Δct values were calculated according to
Δct = ct(gene of interest)-ct(b-actin). For determination
of relative mRNA levels the 2
-ΔΔct was calculated where
ΔΔct = Δct(b-actin)-Δct(gene).
Chromatin Immunoprecipitation (ChIP)
For ChIP assays a total number of 3 × 10
7 ECC-1 cells
were analysed, either transfected with control pcDNA3,
Snail-HA or Slug-HA vectors. The ChIP experiments
were essentially performed as indicated in the manufac-
turer’s protocol (Cell Signaling, Beverly; USA). In brief,
cells were fixed by 1% formaldehyde in PBS. Nuclei
were isolated according to the protocol and the chroma-
tin was digested by micrococcus nuclease treatment for
20 min at 37°C, resulting in DNA-fragments of 150-900
bps in length. Subsequent lysis of the nuclei was
achieved by sonification. The solution was cleared by
centrifugation and the DNA fragments were in the solu-
ble phase. Immunoprecipitation reactions were per-
formed over night at 4°C using antibodies against HA
and b-catenin and a rabbit IgG as negative control, and
aa n t i - H i s t o n eH 3a n t i b o d ya sap o s i t i v ec o n t r o l .T h i s
was followed by incubation of the immunoprecipitation
for another 2 h at 4°C with the protein G magnetic
beads. The beads were pelleted by a magnet, several
times washed and finally eluted and thereby reverse
crosslinked for 30 min at 65°C. The chromatin was
finally purified by micro spin columns. 2 μlo ft h e
appropriate DNA were analysed by qRT-PCR. All sam-
ples were examined in triplicates. The non-immunopre-
cipitated, so-called input control served as a positive
control, another positive control for the efficiency of the
procedure is the immunoprecipitation with H3-antibody.
As a negative control rabbit IgG was used. E box speci-
fic primers for qPCR were designed with the DNA Star
Program and were produced by MWG Eurofines (Ebers-
berg, Germany). Primers used for determining immuno-
precipitated chromatin-fragments were as follows: E1 fw
5′-CCCAGAGAAGACACACCACA-3′;E 1r e v5 ′-CAA
CTTGTTGCCCCATCA-3′;E 2f w5 ′-GCCCAGCCC
TAATTTTGTATT-3′;E 2r e v5 ′-AAAATAAAAGGC
CAGGCACA-3′;E 3f w5 ′-CCCCCTCTTTCAGACC
CTTA-3′;E 3r e v5 ′-GGGACATTTTCCGTGACAGT-3′;
E4 fw 5′-TGGGATTTTCTGGGTGCTT-3′;E 4r e v5 ′-
ACGCAACAGAGCATCAAGG-3′;E 5f w5 ′-GTCCACT
CAGTGCATGGTCA-3′;E 5r e v5 ′-GATTCCTGCTGC
GGGTAG-3′;E 6f w5 ′-AACACGCTGAGGACGAAG-3′;
E6 rev 5′-GAAGGGGATGCTCCCTTAG-3′;E 7f w5 ′-
GTTTCCTCTGCTGTCACCTG-3′; E7 rev 5′-CCATAG
TGCCAGCTTCAGTT-3′;E 8f w5 ′-GCTGTGCTCAG
GAAATGTGA-3′;E 8r e v5 ′-CCCAACTTCTGCAA
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3′;E 9r e v5 ′-TTGAACTCCTGGGCTCAAGT-3′;L e f - 1
(1) fw 5′-TACCATCCTTTCGGTGTTCCC-3′; Lef-1 (1)
rev 5′-GACAGAGCTTGGAGGCTGAA-3′;L e f - 1( 2 )f w
5′-AGCTCCTTCCTTCTCGATCCTGT-3′; Lef-1 (2) rev
5′-TTTCCTCCAGCTCTCTGGTGTCTT-3′;L e f - 1( 3 )
fw 5′-TTCTCCTCCTAAAGGCTGGGCAAA-3′;L e f - 1
(3) rev 5′-TCGACTCAGTCTCACAAGACTCCC-3′;
Lef-1 (4) fw 5′-ACTGAACAATCCACTCCTAAGCGG-
3′;L e f - 1( 4 )r e v5 ′-TCACTCACTGAAGGACAC
TTGGGT-3′.
RNA Ligase Mediated Rapid Amplification of cDNA Ends
(RLM-RACE)
Total RNA was isolated using the Qiagen RNeasy mini
kit (Qiagen, Hilden, Germany). First Choice RLM-RACE
(Ambion by Applied Biosystems, Darmstadt, Germany)
kit was used as described in the manufacturer’s protocol.
In brief, after the CIP-treatment RNA was purified using
an Acid-Phenol-Chloroform extraction. Tabacco Acid
Pyrophosphatase (TAP)-treatment, ligation of the 5′-
RACE-adapter and the convertion into cDNA by using
random hexameres was done as recommended. For the
nested PCR reaction L1CAM exon1 specific reverse pri-
mers were used. L1-exon1 outer rev 5′- ttcctcggggatctg-
gataa-3′, L1-exon 1 inner rev 5′- tagtatCTCGAG
ggaggagaggccacacgta-3′; XhoI binding site in capital let-
ters for cloning into pcDNA3 vector for sequencing pur-
poses. Sequencing reactions were performed at GATC
(Konstanz, Germany).
In silico promoter analysis
The sequence used for the in silico analysis of transcrip-
tion start sites and predicted transcription factor binding
sites is accessible at [GeneBank:U52112.29]. According to
this sequence promoter 1 is located from 42.468nt to
39.083nt (-3385nt) with exon 0 starting at position 39083.
Promoter 2 is located at 33.034nt to 28.885nt (-4149nt).
HUSAR Bioinformatics lab http://genome.dkfz-heidelberg.
de/ software was used to identify TSS. HUSAR accesses
different databases to predict TSS like DOOP, CAGE,
DBTSS, and MBPromDB. Transcription factor analysis
was performed using Alibaba 2.1 software at http://www.
gene-regulation.com. In a second step further factors
could be analysed using HUSAR database http://genome.
dkfz-heidelberg.de. Lef-1 binding sites were identified
using Footer 2.0 analysis tool [28-30]. Transcript variant
analysis was performed using http://www.ensembl.org.
Statistical analysis
For the analysis of statistical significance the Student’s t-
test was used. P-values in the figures are indicated as
follows: *< 0.05, **< 0.01 ***< 0.001.
Results
b-catenin and Slug can regulate L1CAM in endometrial
carcinoma
Recent papers suggested a role of the transcription fac-
tors Slug and b-catenin in L1CAM regulation [12,24,26].
To confirm a role of these transcription factors in EC,
we examined whether overexpression of Slug or a stabi-
lised, constitutively active form of b-catenin (S33Y) in
EC cell lines resulted in augmented L1CAM levels.
Indeed, b-catenin (S33Y) overexpression strongly upre-
gulated L1CAM mRNA levels in ECC-1 cells but only a
minor effect was observed in Hec-1A cells (Fig. 1A). In
contrast, overexpression of Slug showed highest induc-
tion of L1CAM in Hec-1A cells (Fig. 1B). These results
were confirmed at the protein level by Western blot
analysis of transfected cells (Figs. 1C and 1D).
In silico analysis of the L1CAM promoter region
To further analyse this regulation, we investigated the
structure of the L1CAM promoter in more detail. Given
the conflicting data in the literature, we carried out an
in silico analysis of putative TSS in the L1CAM gene
using various bioinformatics tools. As indicated in Fig.
2A, four of the algorithms (DOOP, CAGE, DBTSS,
MBPromDB) employed by a HUSAR analysis predicted
a TSS in front of exon 1. The CAGE database suggested
an additional TSS in front of exon 0. We termed the
regions upstream of exon 0 as “promoter 1” and the 5′-
sequence in front of exon 1 as “promoter 2”.
We next searched for respective binding motifs in the
two promoter regions. As indicated in Fig. 2B and 2C
we identified several E-boxes for the binding of Slug/
S n a i la sw e l la sb i n d i n gs i t e sf o rb-catenin/TCF-LEF
(Fig. 2B and 2C). E-boxes were numbered E1-E9 and
binding sites for b-catenin/TCF-LEF were labelled as
LE1-4 (Fig. 2B). The respective DNA-binding sites are
shown in Fig. 2C.
Identification of in situ transcription start sites by 5′-RLM-
RACE
Next, we investigated the site of transcriptional initiation
of the human L1CAM gene in endometrial carcinoma
cell lines. Therefore, we selected the L1CAM positive
cell lines ECC-1, Hec-1A, Hec-1B and SPAC-1L and
determined the TSS using RLM-RACE technique. In
brief, the mRNA from each cell line was decapped and
an 5′ RACE adaptor was ligated to the 5′-mRNAs. The
5′-ends were amplified in two consecutive PCR reactions
(see Fig. 3A) and the products were separated by gel
electrophoresis (Fig. 3B and 3C). The resulting frag-
ments varied between 150 and 500 bp, were subcloned
and sequenced. In ECC-1 cells the longest transcript
comprised exon 0, a 167 bp sequence derived from the
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Page 4 of 14intron 1 followed by the coding exon 1 (Fig. 3D). In
Hec-1B cells, the exon 0 was clearly not present but
i n s t e a da2 9 1b pf r a g m e n to fi n t r o n1d i r e c t l yf o l l o w e d
by exon 1 was identified. In addition a weaker bypro-
duct of 300 bp was detected that upon sequencing was
unrelated to L1CAM. In SPAC-1L and Hec-1A cells the
5′-end of the mRNA started with exon 1. Thus, the
TSSs for L1CAM transcripts are variable in EC cell lines.
Luciferase activity assays for promoter 1 and 2
We next asked whether both promoter regions were func-
tionally active. We constructed a series of luciferase-repor-
ter plasmids covering approximately. 3.5 kb upstream
exon 0 (constructs L1-P1-P3) (Fig. 4A). Likewise, similar
constructs were generated encompassing approximately
4.0 kb upstream of exon 1 (constructs L1-A to L1-F) (Fig.
4C). Activation of transcription was determined after tran-
sient transfection into Ishikawa EC cells that do not
express L1CAM. Therefore, a competition for transcrip-
tion factors with endogenous L1CAM expression can be
excluded [24]. Luciferase activity with 50-80 -fold higher
levels as compared to the promoter-less control plasmid
(pGl3-basic) was recorded for L1-A to L1-D whereas the
constructs L1-E and -F did not show activity (Fig. 4D).
Interestingly, the activity of L1-A was quite similar to L1-
D although a sequence of nearly 3.5 kb had been deleted.
Thus, a 487 bp sequence upstream of exon 1 was sufficient
to initiate transcription (see below). Promoter 1 constructs
(L1-P1 to L1-P3) also gave high luciferase signals with
strongest activity of L1-P1 and -P3 constructs (Fig. 4B).
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Figure 1 L1CAM mRNA and protein levels in endometrial carcinoma cell lines overexpresssing transcription factors b-catenin or Slug.
(A) Regulation of L1CAM expression after transfection of a point mutated, constitutively active form of b-catenin (S33Y) or control pcDNA3
plasmid as determined by qRT-PCR using specific primers. (B) Regulation of L1CAM levels after overexpression of a HA-SLUG or control plasmid.
Means ± SD from n = 3 independent experiments are shown. (C) Western blot analysis for L1CAM and b-catenin as well as GAP-DH, used as a
loading control. (D) Western blot analysis for L1CAM and anti SLUG as well as GAP-DH, used as a loading control. A representative experiment
from n = 3 is shown.
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together with expression plasmids for Snail, Slug and sta-
bilised b-catenin (S33Y). As shown in Fig. 4E, b-catenin
co-expression increased the promoter activity up to 4-fold
compared to the empty pcDNA3 vector. The enhanced
activity was seen for all constructs from L1-P1 to -P3 (Fig.
4E). There was also an activating effect (2-3 fold) by Slug
overexpression on the activity of L1-P1 and -P2, respec-
tively (Fig. 4E). Interestingly, overexpression of Snail rather
inhibited activity and this effect was most prominent for
the L1-P1 and -P3 constructs.
A similar analysis carried out on promoter 2 con-
structs L1-A to L1-D showed a different pattern (Fig.
4F). Compared to the empty pcDNA3 vector control,
only Slug co-transfection showed increased activity on
L1-A, -B and -C constructs. In contrast, overexpression
of b-catenin or Snail, respectively, resulted in weak inhi-
bitory or no effects (Fig. 4F). All co-transfected plasmids
Figure 2 In silico characterisation of the L1CAM promoter.( A) Schematic illustration of the L1CAM promoter region according to the
Ensembl database. Exon 1 contains the translational start codon (ATG) and a transcription start sites (TSS) predicted by the indicated databeses
DOOP, CAGE, DBTSS, MBPromDB. The upstream sequence of appr. 4100 bp was identified as promoter 2. The non-coding Exon 0 (82 bp) is
located appr. 10 kb upstream and is followed by an appr. 4.5 kb promoter region (promoter 1). A second TSS is predicted by the program CAGE.
(B) Schematic illustration of E-boxes and TCF/LEF-1 binding sites in promoter 1 and promoter 2. (C) DNA sequences of E-boxes and Lef-1
transcription factor binding sites in promoter 1 and promoter 2.
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Figure 3 RLM-RACE to determine transcription start sites in endometrial carcinoma cell lines.( A) Schematic outline of the RLM-RACE
reaction consisting of the ligation of the 5’RACE-adaptor followed by 2 nested PCR reactions with outer and inner primers. (B and C) RNA
preparations of Hec-1A, ECC-1, SPAC-1L, and Hec-1B cells were subjected to the RLM-RACE analysis. On the agarose gel the products of the
nested PCR reactions obtained after outer (no product because of low copy number) and inner PCR are shown. Note the different size of
amplified products. The water control served as a negative control without template. (D) Amplified bands were excised from the gel and
subjected to DNA sequencing. The resulting products and the respective TSS are schematically indicated.
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Page 7 of 14Figure 4 Luciferase reporter assays for L1CAM promoter 1 and promoter 2. (A and B) Schematic illustration of luciferase promoter
constructs of variable length. The E-boxes (E1-E9) and LEF-1 binding sites (LE1-LE4) have been labelled in a consecutive fashion and are
indicated. Note that the constructs contain variable number of E-boxes and LEF-1 binding sites and are referred to as L1-P1 to L1-P3 (from
promoter 1) and A-F (from promoter 2). (C and D) Luciferase activity assay in Ishikawa cells using the indicated promoter constructs. Values have
been normalized to the internal control (renilla) to account differences in transfection efficiency. The pGl3 vector was used as negative control
and pGl3-SV40 as positive control. Luciferase activity was determined after 48 h. A representative experiment from each n = 4 is shown. (E)
Luciferase activity assay of promoter 1 reporter constructs L1-P1 to -P3 in Ishikawa cells using the indicated constructs in combination with
overexpression of Snail-HA, Slug-HA, stabilised b-catenin or pcDNA3 negative control. (F) Luciferase activity assay of promoter 2 reporter
constructs A-D in Ishikawa cells using the indicated constructs in combination with overexpression of Snail-HA, Slug-HA, stabilised b-catenin or
pcDNA3 negative control. Data ± SD of a representative experiment from n = 3 is shown. (*** p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, n.s. not
signicicant).
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Page 8 of 14were inhibitory for the minimal promoter construct L1-
D (Fig. 4F).
Snail/Slug ratios determine activation or inhibition
Snail and Slug are known to bind E-boxes with different
binding affinities [31]. To further study the opposing
effects of Snail and Slug we investigated the minimal
promoter 2 reporter plasmid L1-D. Co-transfection of
Snail or Slug expression plasmids with the reporter con-
struct led to suppression of luciferase activity (Fig. 5A).
When the remaining E-box in L1-D was deleted (L1-
D*), the suppressive activity vanished (Fig. 5A).
In contrast, the previous results with longer reporter
constructs had indicated that both transcription factors
had rather opposing effects. Slug overexpression was
found to activate whereas Snail was found to suppress
promoter activity (see Fig. 4E &4F). To study whether
both transcription factors can compete for binding to
the E-boxes we over-expressed various ratios of Snail
and Slug. The co-transfection of the L1-A reporter plas-
mid with an excess of Slug resulted in activation of luci-
ferase activity but this effect was reversed when Snail
was in excess (Fig. 5B).
Differential promoter usage after TGF-b1 treatment
We have shown before that TGF-b1 treatment of ECC-1
and Hec-1A induced an EMT-like phenotype, i.e. down-
regulation of the epithelialm a r k e rE - C a d h e r i na n du p -
regulation of vimentin but also L1CAM [24]. In order to
analyse which L1CAM promoter sites might be used in
this process, both cell lines were treated for 5 days with
TGF-b1 and subsequently transfected with luciferase
reporter constructs. In Hec-1A cells, only promoter 2
constructs (L1-A, -B and -D) showed enhanced activity
after TGF-b1 treatment (Fig. 6A). Conversely, in ECC-1
cells only promoter 1 constructs (L1-P1, -P2, -P3)
revealed augmented activity (Fig. 6B).
Chromatin-IP analysis for promoter binding
To demonstrate the binding of b-catenin/TCF-LEF com-
plex or Slug to both cellular promoter regions, we car-
ried out a Chromatin-IP analysis. ECC-1 and Hec-1A
cells were transfected with pcDNA3 control or stabilised
b-catenin plasmids and Chromatin-IP was carried out
using an anti-b-catenin specific mAb. Likewise, cells
were transfected with control or a Slug-HA plasmid,
respectively, and Chromatin-IP was carried out using an
anti-HA mAb. To quantitatively analyse the binding of
the transcription factors to the predicted binding sites,
the precipitated chromatin was analysed using qRT-PCR
with primers specific for the selected regions.
In Hec-1A cells the overexpression of Slug-HA led to
a strong binding of Slug to the identified E-boxes (Fig.
7A, left panel). Slug binding to promoter 2 was stronger
than to promoter 1, with highest binding to E-box 2.
The b-catenin overexpression in Hec-1A cells led only
to a small increase in binding to the Lef-1 sites. The
constitutive level of bound b-catenin in vector control
transfected cells was also relatively low (Fig. 7A, right
panel). In ECC-1 cells overexpression of Slug only
resulted in an enhanced binding to two of the identified
E-boxes (Fig. 7B, left panel), where the E-boxes E9 and
E7 in promoter 1 were specifically and exclusively
bound by Slug. In ECC-1 cells, the Lef-1 sites were con-
stitutively more occupied than in Hec-1A cells, and
after overexpression of b-catenin a strongly increased
binding to all Lef-1 sites was detectable. Strongest bind-
ing was seen at the LE4 site in promoter 1 (Fig. 7B,
right panel).
For specificity control we confirmed that all immuno-
precipitated DNAs showed no product with off-target
Figure 5 Transcription factor overexpression and L1CAM
promoter luciferase activity. (A) Demonstration that E-boxes are
essential for promoter 2 activity. In the minimally active promoter
construct pGl3-L1-D the E-box (E1) was deleted and analysed in
Ishikawa cells for promoter activity. (B) The ratio of Slug/Snail
determines the outcome of promoter 2 activity. The pGl3-L1-A
promoter constructs was co-transfected with different ratios of Slug
in Ishikawa cells and promoter activity was determined after 48 h.
Data ± SD of representative experiments from each n = 3 is shown.
(*** p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, n.s. not signicicant).
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Page 9 of 14control primers (not shown). This suggested that the
identified binding sites in the L1CAM promoter 1 and
promoter 2 regions were specifically occupied by the
respective transcription factors.
L1CAM expression is correlated with high levels of Slug
in EC lines
We correlated L1CAM mRNA expression levels with
those of b-catenin, Slug and Snail in a panel of 14 EC
cell lines [24,27]. For each cell line we determined the
Δct value of all four markers. Interestingly, when the
levels of Slug expression were plotted vs. L1CAM a sig-
nificant correlation was found (p = 0.0065) (Fig. 8A).
There was no correlation observed between L1CAM
and b-catenin or Snail expression (Fig. 8B and 8C).
These results support the conclusion that Slug rather
than b-catenin is involved in the regulation of L1CAM
in cultured EC cell lines.
Discussion
Recent data have shown that the expression of L1CAM
in tumours is upregulated when EMT is induced by
TGF-b1 treatment [24,26]. To better understand this
process, we have now analysed the human L1CAM gene
in more detail. We provide evidence that the L1CAM
gene has two promoter regions that are both active in
luciferase reporter assays. Our data suggest that both
predicted TSS can initiate transcription utilizing the
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Page 10 of 14alternative promoter region in a cell line specific man-
ner. By co-expression studies we could show that pro-
moter 1 is mostly responsive to b-catenin
overexpression (and to a minor extent to Slug) whereas
promoter 2 responds to Slug only. Despite the ability of
b-catenin to activate promoter constructs in activity
assays, the expression of L1CAM in EC cell lines seems
to dependent mostly on Slug. These results provide new
insights in the transcriptional regulation of L1CAM dur-
ing tumourigenesis.
We initially used a bioinformatics approach to identify
promoter regions in the L1CAM gene as well as RML-
RACE experiments to determine the TSS of L1CAM
specific transcripts. We identified two putative promoter
regions in the human L1CAM gene. Earlier studies had
already described a promoter region in front of the non-
translated exon 0 located > 10 kB upstream the ATG
site [21]. For ECC-1 cells we confirmed the presence of
a TSS in front of exon 0 similar to the reported TSS in
mouse N2A neuroblastoma cells and mouse brain [21].
In addition, in ECC-1 cells we observed an additional
exon of 167 bp that had not been identified before.
Interestingly, in Hec-1B cells a shorter transcript lacking
exon 0 was identified. Whether this band is a product of
alternative transcription initiation is presently unknown.
In EC cell lines such as Hec-1A and SPAC-1L the TSS
was localised directly in front of the ATG site consistent
with an additional promoter site adjacent to exon 1. In
neural tissues and cell lines the latter promoter site has
also been described [20]. When promoter 1 and promo-
ter 2 reporter constructs were assayed in Ishikawa cells,
both regions were found to be functionally active. Thus,
our results obtained in human tumour cell lines recapi-
tulate the findings in neural cells and demonstrate that
the human L1CAM gene has two active promoter ele-
ments that are differentially used.
We identified several binding sites for b-catenin/TCF-
LEF and E-boxes for Slug/Snail in promoter 1 and 2.
The putative binding sites are unevenly arranged and b-
catenin/TCF-LEF sites are mostly located in promoter 1
whereas E-boxes concentrate in promoter 2. Overex-
pression of Snail resulted in suppressed reporter activity.
This suppression can be counteracted by increasing
amounts of Slug as shown by the ratio experiment.
Overexpression of stabilised b-catenin with promoter
1 reporter plasmids resulted in up to 4-fold activation
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Figure 7 Chromatin-IP analysis of promoter 1 and promoter 2 sites.H e c - 1 A( A) and ECC-1 (B) cells were transfected with HA-Slug (left
panels) or b catenin (right panels) or an empty vector control (pcDNA3). After 48 h cells were fixed, genomic DNA was isolated sheared for
Chromatin-IP using antibodies to b catenin or HA. Liberated DNA was subjected to qRT-PCR analysis using primers specific for all E-boxes or Lef-
1 binding sites in the L1CAM promoter 1 or promoter 2 regions. Data ± SD of a representative experiment from n = 3 is shown.
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Page 11 of 14that is consistent with earlier studies [12]. Co-transfec-
tion of Slug resulted in a minor activation. In contrast,
coexpression of Slug activated efficiently promoter 2
reporter constructs whereas no activating effect of b-
catentin was seen. The pattern of differential reactivity
was also noted in Chromatin-IP experiments. Here, Slug
overexpression was most efficient in Hec-1A cells (pro-
moter 2 dependent) whereas stabilised b-catenin was
significantly more active in ECC-1 cells. Finally, overex-
pression of stabilised b-catenin augmented L1CAM
expression only in ECC-1 cells whereas Slug overexpres-
sion activated L1CAM in both ECC-1 and Hec-1A cells.
Collectively, these results demonstrate a differential
usage of promoter sites in the L1CAM gene and support
a role of b-catenin and Slug in the regulation of L1CAM
expression.
Earlier work has suggested a pivotal role of b-catenin
for the regulation of L1CAM [12]. This conclusion was
based on a couple of consistent observations. First, the
authors showed a mouse reporter plasmid (representing
promoter 1 sequences) with an enhanced activity when
co-transfected with b-catenin. They could inhibit the
L1CAM transactivation of the L1CAM promoter con-
struct by a cytoplasmic tail of E-cadherin, that binds
and sequesters b-catenin from binding to TCF-LEF and
by a dominant-negative LEF-1. Further, a siRNAs-
mediated knock-down of b-catenin in colon cancer cell
lines suppressed b-catenin levels and concomitantly
decreased L1CAM expression. Finally, they showed that
b-catenin-TCF/LEF-1 complexes could bind in electro-
phoretic mobility shift assays to an oligonucleotide
derived from the L1CAM promoter region [12]. These
observations were interpreted as a direct effect of b-
catenin/TCF on the L1CAM promoter [12]. However, it
is quite known that Slug is a direct target of b-catenin
signalling [29], [30] and therefore regulatory effects seen
by b-catenin could also be indirect. It is feasible that b-
catenin first up-regulates Slug that then in turn activates
L1CAM expression. A prominent role of Slug in
L1CAM regulation was previously suggested in two
other studies [26,24] and is supported by our analysis of
a panel of EC cell lines that differ in L1CAM expression.
However, it should be kept in mind that the earlier data
were obtained in colon cancer and that fundamental dif-
ferences may exist between colon cancer and endome-
trial cancer. Moreover, mRNA levels of b-catenin might
not fully reflect catenin activity in the cells. Our findings
suggest that Slug plays a major role in the regulation of
L1CAM in endometrial cancer and pancreatic cancer
[26,24]. It is possible, that under EMT conditions aug-
mented levels of Slug suppress cell-cell adhesion by
down-regulating E-cadherin [31] and up-regulation of
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Page 12 of 14L1CAM expression resulting in enhanced cell motility
and invasion [24,26].
An important question is which factors regulate the
promoter usage of the L1CAM gene? A recent study on
L1CAM expression in colorectal cancer has shown that
the L1CAM promoter regions (including promoter 1
and 2) are subject of comprehensive changes in DNA
methylation of CpG islands [32]. This was seen between
different cell lines but also between tumour and normal
tissue of 5 different patients [32]. Moreover, treatment
of cells with the demethylating agent Azacytidine could
alter L1CAM expression in 1 out of 4 cell lines tested.
There is also evidence that histone deacetylase inhibitors
can up-regulate L1CAM expression [33]. Thus, it is
likely that epigenetic factors may have a strong impact
on the regulation of L1CAM and possibly on the usage
of the two promoter regions.
Conclusions
In summary, our results show for the first time that
L1CAM expression in tumours is regulated by two dis-
tinct promoter regions in the L1CAM gene and that
Slug is a relevant transcription factor for its regulation.
The up-regulation of L1CAM during the EMT process
underscores the important role that this molecule plays
in tumour progression.
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